Dynamic Halifax startup ABK Biomedical has engaged Enginuity to deliver engineering support for their ancillary delivery device for OccluRad. ABK are pioneering the use of radio-opaque embolic microspheres in the targeted treatment of tumors. Following early design in Ireland, ABK have brought core engineering to Halifax, in order to advance the device to production.
“Having access to unique creative engineering on our doorstep is key to meeting our investor expectations and delivering on our key business milestones” says Daniel Boyd, Chief Scientific Officer at ABK, adding “proximity is critical to rapid iteration, that’s what ABK needs as we move to the next phase.”
Enginuity are working on refining the device for use in OccluRad embolization microsphere preclinical trials, scheduled in early 2015. Enginuity will also undertake additional development and refinement on the ancillary delivery device for the first round of human testing, preparing for a full commercial launch for the product.
“We’re working hard to get the relevant regulatory approvals in place for Enginuity to provide value to ABK and the many other med tech players blossoming in the Maritimes” adds Ben Garvey, CEO of Enginuity Inc, based on Herring Cove Road in Halifax.
Dr Bob Abraham, ABK’s Chief Executive Officer sees the relationship as key to the successful launch of OccluRad embolization microspheres, adding “Enginuity have the right mix of skills, concise processes and personality to make the difference moving forwards.”